Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 8/20 | 0.50 |
| ▸ | BRAF | P15056 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250589 | 0.90 | KIT (0.67) | KITMEN1NPC1MAPTHTT | |
| SCHEMBL24697059 | 0.85 | KIT (0.62) | KITBRAFMEN1NPC1MAPT | |
| SCHEMBL13202458 | 0.85 | KIT (0.57) | KITARBRAFMEN1NPC1 | |
| SCHEMBL13130573 | 0.85 | KIT (0.62) | KITBRAFMEN1MAPTHTT | |
| SCHEMBL19500723 | 0.85 | KIT (0.61) | KITBRAFMEN1NPC1MAPT | |
| SCHEMBL24696591 | 0.84 | KIT (0.72) | KITBRAF | |
| SCHEMBL16241752 | 0.83 | KIT (0.60) | KITBRAFMEN1NPC1MAPT | |
| SCHEMBL24696421 | 0.83 | KIT (0.70) | KITBRAF | |
| SCHEMBL17696235 | 0.83 | KIT (0.59) | KITBRAFMEN1NPC1MAPT | |
| SCHEMBL16241756 | 0.83 | KIT (0.70) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493473-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493473-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 533/4885AR 3040/4885BRAF 9/4885 |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 533/4885AR 3040/4885BRAF 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.